Integra CEO Expects To 'Lose Some Business' In Neurosurgery As Mayfield Clamp Supply Runs Short Into 2027

Flood damage in Cincinnati will cost $15 million to $20 million in revenue in the fourth quarter, with a similar hit expected in the first quarter of 2027.

Share
Integra CEO Expects To 'Lose Some Business' In Neurosurgery As Mayfield Clamp Supply Runs Short Into 2027

Integra LifeSciences Chairman and CEO Stuart Essig said on the company's third-quarter earnings call that Integra will "lose some business to some of the smaller competition" while it waits for Mayfield neurosurgery supply to return. The Cincinnati flood is expected to cost about $15 million to $20 million of fourth-quarter revenue, and management said the drag runs into the first half of 2027.

What management said about Mayfield

Essig said the constraint is the Mayfield head clamp, a reusable capital product. "We don't have significant inventory of that," he said, and that gap drives the shortfall in the fourth quarter and the first half of 2027. Disposable Mayfield products are still being supplied to customers.

To hold accounts, Essig described a large loaner pool that hospitals can draw on when a device needs repair, extended service contracts on existing units, and incentives for customers to wait until the product returns in the middle of next year. He said most neurosurgeons trained on Mayfield and "really want that product and they want the product back." Customers have used it for "well over 50 years," he said.

Still, he said, "undoubtedly, we'll lose some cases," while voicing confidence in keeping Integra's significant market position once supply returns.

Chief Financial Officer Lea Knight told an analyst that all of the first quarter of 2027 will be affected, with shipments resuming in the second quarter. She said the quarterly hit should be similar to the $15 million to $20 million framed for the fourth quarter, and that guidance will likely assume very limited second-quarter revenue.

What it changes for the numbers

Asked whether deferred sales would come back, Knight said modeling should not assume any meaningful backorder clearance once shipping resumes in the second quarter of 2027. Shipments would restart against demand at that time. She added that the affected product is capital equipment, so Integra can keep supporting customers who already own units, which should help it keep share.

The flood cut third-quarter revenue by about $7 million, the company said. Third-quarter revenue was $411.2 million, at the low end of guidance. Management said its July outlook had contemplated Cincinnati disruption mainly in downside scenarios, on the belief that recovery actions could substantially mitigate it.

The company continues to expect full-year revenue of $1.634 billion to $1.654 billion and adjusted earnings per share of $2.30 to $2.40, consistent with its October 2 update. Neurosurgery still grew 6.5% organically in the quarter despite the roughly $7 million headwind. Integra shares traded at $13.55, up about 2% from the prior close, according to market data as of the report time Wednesday morning.

What to watch

Essig said the Surgimend breast reconstruction approval awaits a successful FDA pre-approval inspection at Braintree, expected next year, with FDA controlling the timing. Management also reiterated a December limited relaunch of Surgimend, while acknowledging some timing risk.

Knight said Integra will give formal 2027 guidance in February, when the first-quarter Mayfield hit becomes a number investors can hold it to.

Sources

More on Integra LifeSciences

All Integra LifeSciences (IART) coverage →